KLAS
4.6.2024 11:01:28 CEST | Business Wire | Press release
Klas, a global leader in rugged edge technology solutions, is proud to unveil its most advanced vehicle data logging solution yet - the TRX D16. This cutting-edge device combines high-performance computing (HPC) and storage into a single platform, revolutionizing ADAS/AD development and data logging for both lab and in-vehicle use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604506618/en/
TRX D16 from Klas - HPC ADAS/AD Development Server & Cloud Scale Data Logging (Photo: Business Wire)
The TRX D16 introduces transformational advancements to in-vehicle computing and logging and unleashes technology confined to the cloud or extremely large loggers up to this point. Now, high-end computing and logging can be fitted to any vehicle platform, allowing engineers to continue pushing the limits of ADAS/AD.
With TRX D16, automotive engineers gain a high-performance and customizable platform to accommodate the evolving vehicle sensor stack and support compute-intensive software development of AI/ML training, inference, and simulation. Furthermore, the platform delivers 200Gbps of sustained logging speeds and 480TB of data storage to capture data from high-speed ethernet-based cameras, with support for denser radar and lidar point cloud captures.
Designed rugged, the TRX D16 is equally at home in the lab and the vehicle. Engineers can transfer the entire development environment workbench to the vehicle for continued development and integration of new functionality with real-world drive test scenarios.
“As a single platform, the multi-purpose TRX D16 minimizes the number of disparate systems in the vehicle and reduces the effort of moving from the lab to the vehicle,” said Frank Murray, CTO of Klas. “By reducing the time spent preparing the vehicle, engineers can focus on productive tasks of real-world validation, which includes high-performance computing for AI testing. At a program level, the result is the improved time to market for new ADAS/AD functionality.”
TRX D16 key features
The TRX D16 is designed rugged to the highest specifications of MIL-STD-461 and 810G/H to withstand the extremes of temperature, vibration and shock.
- High performance computing: AMD EPYC™ 7713P (64 core) processor and up to 768GB of RAM, designed for embedded and harsh environments in vehicles.
- Open GPU options: Numerous GPU PCIe card options are supported, allowing for more flexible and cost-effective AI/ML development environments.
- Hot-swappable storage: 480 TB storage (16x SSDs) split over two removable cassettes allows test vehicles to return to the road in minutes with minimal IT effort.
- High disk write speeds: SAS4 SED drives, plus integrated RAID for secure data capture from an increased number of high-bandwidth sensors.
- High speed connectivity: 2x 100GbE interfaces to transfer valuable data to engineering HIL/SIL workbenches.
- Flexible expansion: 2x PCIe (Gen 4) interfaces for custom I/O - automotive Ethernet, FPGA based SmartNICs, GMSL/FPD-Link/GVIF based cameras, or storage.
To learn more about the TRX D16 HPC server and vehicle data logger or Klas, visit -
https://www.klasgroup.com/markets/automotive/l4-l5-data-logging/
About Klas
Klas is an engineering and design company with over 30 years of experience developing innovative rugged communications solutions for the network edge. The company specializes in integrating enterprise networking capabilities from global IT leaders with purpose-built hardware and software platforms designed to meet market demands and the most stringent environmental requirements. Klas collaborates with strategic partners, including Cisco, Dell, and Microsoft, to support edge deployments in Government, Transportation, and Automotive industries. For more information, visit www.klasgroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604506618/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release
CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla
BMG and Concord Combine to Create World’s Leading Independent Music Company28.4.2026 14:11:00 CEST | Press release
Creates global platform to deliver superior service to artists, songwriters, and partnersUnlocks meaningful value through greater scale and strong cash flow, enabling continued investment in music rights, creative talent, and technologyBob Valentine to serve as CEO and Thomas Coesfeld as Chairman of the combined company, with global headquarters in Nashville and European Headquarters in BerlinCombined company to be named BMG with divisions “BMG Publishing” and “Concord Records” BMG and Concord today announced a definitive agreement to combine their businesses, creating the leading independent music company in the world. Operating under the BMG name, the combined company will bring together two highly complementary businesses to establish a scaled, global company delivering superior service to artists, songwriters, and partners – firmly grounded in an independent, artist-first model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study28.4.2026 14:00:00 CEST | Press release
NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and Disparities by Skin Pigmentation (NeoPODS) study findings were presented from the podium at the Pediatric Academic Society in Boston, MA on Monday, April 27th at 10 am EST by lead author Dr. Heather Siefkes on behalf of colleagues at the University of California, Davis and the University of Mississippi
KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center28.4.2026 11:54:00 CEST | Press release
Delivering up to 130kW of liquid cooling per rack, the solution synchronizes cooling output with IT load in real time within seconds, to support high-density AI, large-scale computing, and HPC deployments, while reducing build time by 70% KAYTUS, a leading provider in AI infrastructure and liquid-cooling solutions, announced that its AI Compute Pod has received both the 2026 iF Design Award and Red Dot Award. This dual recognition not only stems from its outstanding performance in green, low-energy operation—achieving up to 130 kW cooling capacity per rack and a PUE as low as 1.1 through optimized thermal and power design—but also from its innovative approach to intelligent control and efficient O&M. The solution enables second-level synchronization between cooling and IT workloads, and leverages a dual-group control strategy to improve cooling energy efficiency by over 10%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom